Latest Medical Devices News

Anteris Technologies has updated the timetable for its Australian capital raising, delaying settlement to November 4 and the start of trading for new securities to November 5. The company also highlights restrictions on U.S. investors acquiring its CDIs.

Orthocell has completed its first Remplir™ surgical case in Hong Kong, marking a pivotal step in its Asian commercialisation strategy. The launch at the Hong Kong Orthopaedic Association Congress and partnership with MontsMed set the stage for broader regional growth.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.

ResMed Inc. reported a robust 9% increase in net revenue for Q1 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. Despite ongoing patent litigation, the company delivered a 12% rise in net income and boosted shareholder returns with a $150 million share repurchase.

EMVision Medical Devices has successfully closed an oversubscribed Share Purchase Plan, raising $2 million and bringing total recent capital to $14 million. This funding positions the company to advance pivotal clinical trials and regulatory milestones for its innovative neurodiagnostic devices.

Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

Mach7 Technologies reports a pivotal first quarter for FY26, marked by the initial go-live of a major U.S. Veterans Health Administration contract, leadership changes, and a strategic business reset.

BPH Energy’s September quarter report highlights pivotal developments across its investees, from a critical judicial review in offshore petroleum to breakthroughs in AI medical devices and clean hydrogen production.

Control Bionics reports a strong start to FY26 with nearly 10% revenue growth, expanded US reimbursement coverage, and advancing commercialization of its NeuroNode and NeuroStrip technologies.

CONNEQT Health reports robust 50% quarter-on-quarter growth in Pulse device sales and launches a new pricing strategy to boost recurring revenue. The company also secures a significant US clinical trial contract and advances cost-cutting efforts.